Veracyte

Patients with luminal breast cancer subtypes may do just as well without anthracycline-based chemo and avoid unnecessary toxicities, a study showed.

The firm posted $29.7 million in revenues, up about 15 percent from $25.8 million in Q4 2018 and slightly above the analysts' average estimate of $29.5 million.

Most diagnostics companies saw increases in share prices compared to last year, resulting in a significant jump in the 360Dx Index.

Veracyte has also acquired Nanostring's Prosigna breast cancer and LymphMark lymphoma assays and plans to develop diagnostic tests using the nCounter platform. 

Of the 28 companies in the index, 21 companies' share prices increased while the share values of 7 declined month over month. 

For the three months ended Sept. 30, the firm reported total revenues of $31.0 million, beating analysts' average estimate of $30.1 million.

For the three months ended June 30, the genomic testing firm reported total revenues of $30.1 million.

Other big gainers last month included Accelerate Diagnostics and Natera, and share prices of 23 of the 27 companies in the index increased month over month.